Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021GlobeNewsWire • 02/09/21
Esperion Therapeutics: Deeply Undervalued With An Extremely High Short InterestSeeking Alpha • 01/30/21
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor ProgramGlobeNewsWire • 01/13/21
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in SwitzerlandGlobeNewsWire • 12/16/20
First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® ▼ (bempedoic acid and ezetimibe) tablet approved in SwitzerlandBusiness Wire • 12/16/20
Why Is Esperion Therapeutics (ESPR) Up 17.5% Since Last Earnings Report?Zacks Investment Research • 12/02/20
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study SubgroupsGlobeNewsWire • 11/13/20
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated NotesGlobeNewsWire • 11/12/20
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated NotesGlobeNewsWire • 11/10/20
Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/03/20
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company UpdateGlobeNewsWire • 11/02/20
Earnings Preview: Esperion Therapeutics (ESPR) Q3 Earnings Expected to DeclineZacks Investment Research • 10/26/20
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad CholesterolGlobeNewsWire • 09/28/20
Esperion Therapeutics (ESPR) Up 12.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/09/20